Glaukos Corporation faces a telling week: the Street keeps lifting price targets while the stock itself gives back ground, leaving a widening gap between analyst conviction and near-term price action.
The analyst backdrop is the most active angle right now. Targets have moved in one direction only across the past six weeks — up. Needham raised its target to $150 from $136 this week, maintaining its Buy. Citigroup lifted to $162 from $140 last week. BTIG has reiterated Buy at $162 twice since May. The consensus mean now sits at $157.50, roughly 24% above the current $127.53 close. Every recent action has been a raise, with no downgrades or cuts in the mix — a directionally clean picture from the covering universe. Bulls point to the iDose and Epioxa product launches expanding addressable markets in glaucoma and keratoconus, while bears flag slower-than-expected uptake, reimbursement risks, and intensifying competition as the key overhangs.
Positioning is the least alarming part of the setup. Short interest eased another 9% on the week to 5.3% of the free float — about 3.1 million shares — continuing the retreat that began ahead of the May 28 earnings print. That's down from a recent peak near 6% in early May. The borrow market is under no stress: cost to borrow has dropped 22% this week alone to just 0.35%, a multi-month low, and availability is exceptionally loose at roughly 24x the current short position. There is no squeeze pressure building in the lending market. The ORTEX short score ticked down to 39.9 from 41.5 two weeks ago, moving it further from any alarm territory.
Options flow, however, marks a sharp contrast with that relaxed borrow picture. The put/call ratio collapsed to 0.61 on Tuesday — well below its 20-day mean of 11.9 and about 1.4 standard deviations below average. As noted in last week's note, the PCR had already swung hard from its May 18 peak of 27.6 toward call dominance following the earnings release. That call-heavy skew has broadly held, though the 20-day mean remains inflated by the pre-earnings hedging period still in the window. The directional read is that options traders remain more interested in upside than downside for now.
The insider picture is worth a brief note. The 90-day insider net figures show net selling of roughly $10.9 million — COO Joseph Gilliam sold nearly $2.8 million of stock in early May at $143, and CFO Alex Thurman sold $1.4 million at $140 the day before. Those prices now sit well above the current $127.53 level, a reminder that insiders were active distributors near the post-earnings highs. The significance scores on these trades are modest, and pre-planned trading plans cannot be ruled out, but the directional flow from named executives has been one-way out.
On the earnings front, the two most recent prints produced very different reactions: the May 28 report brought a 6% one-day drop before recovering 11% over the following five days, while the April 29 print delivered a 20% jump with a 13% five-day follow-through. The next event is scheduled for July 29. With the stock now down 11% from its one-month high and analysts still uniformly constructive, the July print shapes up as the next moment where the gap between the Street's $157.50 mean target and the market's current $127.53 verdict gets tested.
See the live data behind this article on ORTEX.
Open GKOS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
